Clinical Outcomes of HPV-associated and Unassociated Endocervical Adenocarcinomas Categorized by the International Endocervical Adenocarcinoma Criteria and Classification (IECC).


Journal

The American journal of surgical pathology
ISSN: 1532-0979
Titre abrégé: Am J Surg Pathol
Pays: United States
ID NLM: 7707904

Informations de publication

Date de publication:
04 2019
Historique:
pubmed: 6 2 2019
medline: 14 1 2020
entrez: 6 2 2019
Statut: ppublish

Résumé

The International Endocervical Adenocarcinoma Criteria and Classification (IECC) categorizes endocervical adenocarcinomas (ECAs) on the basis of morphologic features linked to etiology (ie, human papilloma virus [HPV] infection), resulting in separation of ECAs into HPV-associated (HPVA) and unassociated or non-HPVA (NHPVA) types. NHPVAs are reported to be large and present at high stage in older individuals. Our aim was to examine the clinical outcomes in these tumor types. Full slide sets of 205 ECAs were collected from 7 institutions worldwide and classified on the basis of IECC criteria and the presence or absence of HPV. Clinical and morphologic parameters were correlated with follow-up data. Statistical analysis of overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS) were conducted using the Kaplan-Meier survival analysis and compared using the log-rank test for univariate analysis. Multivariate survival analysis was conducted, and the survival endpoints considered were OS, DFS, and PFS. Statistically significant survival differences (OS, DFS, and PFS) were found when comparing the following categories: HPVA>NHPVA (ie, survival was superior in the setting of HPVAs), including patients treated with surgery followed by adjuvant therapy; usual-type HPVA>mucinous HPVA; FIGO grade 3 HPVA>NHPVA; HPVA>NHPVA, both with lymphovascular invasion; and HPVA>NHPVA in patients with pelvic recurrences. Although there were trends favoring HPVA outcomes over those of NHPVA, these differences were not statistically significant in the following categories: mucinous HPVA versus NHPVA; HPVA versus NHPVA, both with lymph node metastases at presentation; and HPVA versus NHPVA in patients with distant metastasis. Survival for both HPVA and NHPVA was similar when surgery without adjuvant therapy was used. FIGO grading did not have prognostic significance in HPVAs. Multivariable analysis of HPVAs indicated nearly significant statistical associations between stage and both OS and DFS (P=0.07 and 0.06, respectively), and between Silva invasion pattern and OS (P=0.09). Multivariate analysis of NHPVAs indicated a statistically significant association between OS and age (P=0.03), stage (P=0.02) and tumor size (P=0.002), and between DFS and stage (P=0.004) and tumor size (P=0.004). Multivariate analysis of HPVAs and NHPVAs together revealed nearly significant associations between OS and HPV status and stage (both [P=0.06]). For DFS, stage was a significant variable (P=0.04), whereas HPV status and tumor size were nearly significant (P=0.06 and 0.07, respectively). Clinical outcome studies support the idea that the IECC classification not only separates ECAs on the basis of HPV status (usually assessed on H&E slides), but also has important clinical relevance.

Identifiants

pubmed: 30720532
doi: 10.1097/PAS.0000000000001224
pmc: PMC6417947
mid: NIHMS1518180
doi:

Types de publication

Journal Article Multicenter Study Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

466-474

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States

Références

Am J Surg Pathol. 2011 May;35(5):633-46
pubmed: 21490443
Am J Surg Pathol. 2018 Feb;42(2):214-226
pubmed: 29135516
Am J Surg Pathol. 2000 Oct;24(10):1414-9
pubmed: 11023104
Int J Gynecol Cancer. 2018 Jan;28(1):99-106
pubmed: 29206664
Am J Surg Pathol. 2018 Aug;42(8):989-1000
pubmed: 29851704
Gynecol Oncol. 2018 Jul;150(1):56-60
pubmed: 29859673
Mod Pathol. 2019 Feb;32(2):269-279
pubmed: 30258209
Am J Surg Pathol. 2019 Jan;43(1):75-83
pubmed: 29877920
Am J Surg Pathol. 2016 Feb;40(2):262-9
pubmed: 26523540
Am J Surg Pathol. 2015 Nov;39(11):1449-57
pubmed: 26457350
Am J Surg Pathol. 2007 May;31(5):664-72
pubmed: 17460448
Int J Gynecol Pathol. 2013 Nov;32(6):592-601
pubmed: 24071876
J Natl Compr Canc Netw. 2018 Feb;16(2):170-199
pubmed: 29439178

Auteurs

Simona Stolnicu (S)

Departments of Pathology.

Lien Hoang (L)

Vancouver General Hospital.

Derek Chiu (D)

OVCARE and British Columbia Cancer Research Centre, Vancouver, BC, Canada.

Orsolya Hanko-Bauer (O)

Surgery, University of Medicine and Pharmacy of Targu Mures, Targu Mures.

Cristina Terinte (C)

Regional Institute of Oncology, Iasi, Romania.

Anna Pesci (A)

Ospedale Sacro Cuore Don Calabria, Negrar, Italy.

Sarit Aviel-Ronen (S)

Sheba Medical Center, Tel-Hashomer, Ramat Gan, Israel.

Takako Kiyokawa (T)

The Jikei University School of Medicine, Tokyo, Japan.

Isabel Alvarado-Cabrero (I)

Hospital de Oncología Mexico City, Mexico City, Mexico.

Esther Oliva (E)

Massachusetts General Hospital, Boston, MA.

Kay J Park (KJ)

Departments of Pathology.

Nadeem R Abu-Rustum (NR)

Surgery, Memorial Sloan Kettering Cancer Center.
Weill Cornell Medical College, New York, NY.

Robert A Soslow (RA)

Departments of Pathology.
Weill Cornell Medical College, New York, NY.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH